Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
BTAI
BTAI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest BTAI ETF News Today | Earnings, Events & Price Alerts
BTAI News
Halper Sadeh Investigates BioXcel Therapeutics for Potential Breach of Fiduciary Duties
Jan 15 2026
Businesswire
BioXcel Seeks FDA Approval for At-Home Use of IGALMI® in Agitation Treatment
Jan 09 2026
Newsfilter
BioXcel Seeks FDA Approval for At-Home Use of IGALMI in Agitation Treatment
Jan 07 2026
NASDAQ.COM
BioXcel Therapeutics Hosts Virtual Roundtable on Self-Administered Treatment Opportunities
Dec 03 2025
Globenewswire
BioXcel Hosts Roundtable on Self-Administered Treatments for 77M Agitation Episodes
Dec 03 2025
Newsfilter
BioXcel Therapeutics to Celebrate Major Neuroscience Achievement by Ringing Nasdaq Closing Bell on October 14
Oct 13 2025
Newsfilter
BioXcel Meets Nasdaq Listing Requirements Again
Sep 18 2025
SeekingAlpha
BioXcel Medication Eases Home Agitation in Patients with Schizophrenia and Bipolar Disorder
Sep 10 2025
Benzinga
BioXcel Therapeutics Announces Encouraging Preliminary Efficacy Results from SERENITY At-Home Phase 3 Safety Trial for Agitation Linked to Bipolar Disorders or Schizophrenia
Sep 10 2025
Newsfilter
BioXcel Therapeutics Announces Encouraging Preliminary Efficacy Results from SERENITY At-Home Study
Sep 10 2025
NASDAQ.COM
EXCLUSIVE: Top 20 Most-Searched Stocks on Benzinga Pro for August – How Do Opendoor, Palantir, BitMine Immersion, and Apple Rank?
Sep 02 2025
Benzinga
BioXcel Plans to Pursue Approval for Home Use of Agitation Medication Following Positive Study Results
Aug 27 2025
Reuters
BioXcel Pursues FDA Approval for Expanded Label on Schizophrenia Therapy
Aug 27 2025
Benzinga
BioXcel Therapeutics Reports Successful Primary Endpoint Achievement in SERENITY At-Home Phase 3 Safety Trial, Supporting sNDA for IGALMI® Label Expansion
Aug 27 2025
Newsfilter
BioXcel's SERENITY Phase 3 Study of BXCL501 Achieves Primary Objective in At-Home Setting
Aug 27 2025
NASDAQ.COM
BioXcel Therapeutics Reports Successful Primary Endpoint Achievement in SERENITY At-Home Phase 3 Safety Trial, Supporting sNDA for IGALMI® Label Expansion
Aug 27 2025
Newsfilter
Show More News
